A Multicenter Medical Safety Follow-up Study for Patients With Partial Onset Seizures Who Received More Than 28 Days of Total Exposure to BGG492 in Studies CBGG492A2207 and/or CBGG492A2212

Trial Profile

A Multicenter Medical Safety Follow-up Study for Patients With Partial Onset Seizures Who Received More Than 28 Days of Total Exposure to BGG492 in Studies CBGG492A2207 and/or CBGG492A2212

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Selurampanel (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 11 Apr 2016 Trial protocol (Primary endpoints,time frame for primary endpoints and treatment ) amended.
    • 06 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials. gov.
    • 06 Jan 2015 Planned End Date changed from 1 Nov 2014 to 1 Jun 2015, according to ClinicalTrials. gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top